Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Marc Ladenheim

Cardiovascular Disease Burbank, CA Medical Doctor

NPI 1558363416 CMS profile 251703

2701 W Alameda Ave, Ste 607, Burbank, CA 91505

Open in the dashboard

General payments

$14,892

416 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Marc Ladenheim of Burbank, CA is reported in the CMS Open Payments database as having received $14,892 across 416 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,256 53
2023 General $6,993 76
2022 General $1,454 73
2021 General $1,656 82
2020 General $1,222 57
2019 General $2,311 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Ladenheim
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Marc Ladenheim were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Marc Ladenheim Cardiovascular Disease median Middle half National median
2019 $2,311 $450 $127–$1,392 $163
2020 $1,222 $242 $77–$751 $114
2021 $1,656 $335 $101–$1,037 $132
2022 $1,454 $395 $121–$1,211 $149
2023 $6,993 $443 $136–$1,283 $160
2024 $1,256 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Medtronic, Inc. $5,544 3 payments
  2. AstraZeneca Pharmaceuticals LP $1,034 46 payments
  3. Novartis Pharmaceuticals Corporation $926 52 payments
  4. Boston Scientific Corporation $857 25 payments
  5. Lilly USA, LLC $764 41 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $594 26 payments
  7. Novo Nordisk Inc $468 28 payments
  8. Cardiovascular Systems Inc. $455 6 payments
  9. Abiomed $396 2 payments
  10. Pfizer Inc. $328 13 payments
  11. Other $3,526 174 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $8,546 403 payments
  2. Debt forgiveness $5,535 2 payments
  3. Travel and Lodging $586 2 payments
  4. Education $225 9 payments
Products named General payments · program years 2019–2024
  1. JARDIANCE Diabetes $587 33 payments
  2. ENTRESTO $554 34 payments
  3. FARXIGA $543 21 payments
  4. JARDIANCE Diabetes $543 24 payments
  5. BRILINTA $489 22 payments
  6. Coronary Orbital Atherectomy System $441 5 payments
  7. Impella $396 2 payments
  8. LEQVIO $262 12 payments
  9. Repatha $244 10 payments
  10. ELIQUIS $243 14 payments
  11. Other $6,944 340 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

2,483

Median for Cardiology: 2,533

Drug cost

$420,755

Median for Cardiology: $485,213

Branded share of claims

24%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 81 $84,143
Xarelto Rivaroxaban Brand 77 $74,987
Jardiance Empagliflozin Brand 29 $46,571
Entresto Sacubitril/Valsartan Brand 29 $39,308
Farxiga Dapagliflozin Propanediol Brand 23 $24,916
Mounjaro Tirzepatide Brand 19 $24,456
Repatha Sureclick Evolocumab Brand 25 $19,427
Januvia Sitagliptin Phosphate Brand 13 $19,351
Ozempic Semaglutide Brand 12 $14,660
Praluent Pen Alirocumab Brand 14 $12,566

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$50,784

Of which drugs: $247

Medicare patients

182

Average age 77

Services billed

610

73 women, 109 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Arthritis 52%
Diabetes 50%
Atrial fibrillation 32%
Heart failure 25%
Depression 23%
Chronic kidney disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 13 49 $247

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $64
  • Boehringer Ingelheim Pharmaceuticals, Inc. $18
$82 29 —
ZEPBOUND
  • Lilly USA, LLC $77
$77 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $62
$62 23 —
MOUNJARO
  • Lilly USA, LLC $55
$55 19 —
Repatha
  • Amgen Inc. $43
$43 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

416 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record